• Investigating a new option for CF patients with MRSA

    AVAIL is a Phase 3 clinical study of the investigational drug AeroVanc for persistent methicillin-resistant Staphylococcus aureus, or MRSA, lung infection in cystic fibrosis patients

    Learn MoreFind a Site
© Copyright 2019 - The AVAIL Study | Legal Notices & Disclaimer
Information is intended for U.S. subjects and healthcare providers only.